demand first drug proven effect multiple sclerosis betaseron outstrips supply extent lottery used decide patients receive when schering germany launched betaseron last september us country licensed sale doctors registered 80000 ms patients wanted drug the companys computer picked 15000 random begin treatment cost dollars 9500 pounds 6500 year scherings us subsidiary berlex says 20000 patients receiving injections betaseron form betainterferon 20000 preparing start treatment chiron californian biotechnology company manufactures betaseron berlex genetically engineered bacteria increasing production rapidly forecasts us waiting list disappeared 1995 schering hopes submit european licence application betaseron next month european supplies manufactured germanys boehringer ingelheim meanwhile two competing betainterferons developed aresserono switzerland biogen us moving clinical trials ms patients ian broadhurst pharmaceutical analyst bnp capital markets predicts betaseron enjoy two years free competition though could still bring schering dm600m pounds 250m sales 1995 besides interferons many new generation ms drugs various stages research development a bnp report last month listed 25 commercial rd projects progress around world advanced shown table together represent progress broad front ms common disease nervous system young adults affects estimated 2m people worldwide effective ms treatments could give pharmaceutical industry huge new market potential us sales dollars 18bn year according estimate genetic technology news biotechnology newsletter although precise molecular cause ms yet known scientists agree autoimmune disease broad category rheumatoid arthritis diabetes the bodys immune system intended defend germs foreign invaders turns cells the selfattack probably triggered combination genetic environmental factors in ms white blood cells tcells destroy protein sheath called myelin protects nerve fibres this stops nerves working properly patient begins lose control muscles symptoms include partial paralysis blurred vision speech difficulties but progress ms variable in worst cases chronicprogressive ms neurological problems become steadily severe eventually kill patient in relapsingremitting ms disease flares unpredictable intervals may even disappear spontaneously neither betainterferon experimental drugs cure ms first time promise significant amelioration disease until doctors able offer patients comfort therapy painkillers antiinflammatory drugs control symptoms effect underlying disease ms specialists george ebers canadian neurologist university hospital london ontario understandably cautious claims new treatments many false dawns therapies widely used found study ineffective for example hyperbaric oxygen treatment subjecting patient high pressure oxygen became fashionable 1970s discredited 1980s researchers also claimed success drugs cyclophosphamide cyclosporin suppress patients whole immune system turned ineffective ms tested properly the acceptable clinical test doubleblind randomised placebocontrolled trial patients divided random two groups one receives drug identical dummy neither patients investigators know end getting tested conditions patients relapsingremitting ms betaseron reduced number attacks one third reduced significantly amount nerve damage shown magnetic resonance imaging but ian mcdonald london universitys institute neurology points betaseron yet shown effect patients longterm development disability interferons natural proteins perform wide range functions including modulating immune system all three kinds alpha beta gamma tested ms alpha effect gamma made disease worse scientists believe natural gammainterferon may play role progression ms it clear betainterferon brings improvement according aresserono may decrease activity immune cells destroy myelin counteract diseaseenhancing effects gammainterferon the aresserono biogen betainterferons differ slightly betaseron they made genetically engineered mammalian cells rather bacteria cultures as result sugar chains protein surface like natural human interferon unlike schering product in theory could give clinical advantage terms fewer sideeffects improved efficacy evidence show whether work better practice most ms treatments development aim disable specific part immune system responsible ms without suppressing immune functions essential fighting disease those advanced development process include deoxyspergualin dsg natural bacterial extract discovered nippon kayaku japan developed hoechst germany it suppresses harmful tcells may also stimulate regrowth damaged myelin if clinical trial results due next month encouraging hoechst apply marketing licence regulatory approval could follow quickly since dsg genetically engineered product myloral formulation bovine cow myelin developed autoimmune massachusetts biotechnology company it oral tolerance therapy the patient fed protein immune system comes tolerate therefore less inclined attack myelin after promising early results myloral largescale clinical trials copolymer1 cop1 synthetic chemical resembling myelin protein developed teva israel when injected patient decoy attracts immune cells away real myelin it final stage clinical trials at earlier stages development biotechnology industry testing several experimental drugs including antibodies vaccines these aimed either specific types tcell researchers believe responsible immune attack ms antigens myelin provoke attack however vigorous debate ms specialists whether fundamental defect lies narrow subgroup tcells case specific drug could theory cure disease whether wider range immune cells responsible if ms harder treat ebers inclines latter view even says mood among sceptical audience approaching optimism the series continues next month look blood products articles last six months looked pharmaceutical advances following areas sepsis 31 march prostate 25 february wound healing 21 january obesity 23 december contraceptives 12 november anaesthetics 15 october multiple sclerosis selected drugs clinical trials company country lead compound possible launch anergen us mhc peptide complex 1999 aresserono switzerland beta interferon 1996 autoimmune us ai100 bovine myelin 1996 biogen us beta interferon 1995 celsci us tcell vaccine 1998 celtrix us tgfb2 1998 hoechst germany deoxyspergualin dsg 1995 icos us 23f2g mab 1999 immune response us ai208 1999 schering germany beta interferon 1993 teva israel copolymer1 1995 source bnp group equity research